Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 6 | BMC Cancer

Figure 6

From: Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS

Figure 6

Pazopanib suppressed tumor growth in a Hewga-CCS tumor xenograft model. (A) Nude mice were inoculated subcutaneously in the flank with 1 × 107 Hewga-CCS cells. When the tumors reached a palpable size, the mice were treated daily by oral gavage pazopanib (100 mg/kg) or vehicle control, following which tumor size was measured. Bars: SE. * P < 0.05. (B) Representative microscopic images of tumor sections are shown to be stained with hematoxylin/eosin (HE), TUNEL, and Ki-67. Bars in the top rows: 200 μm. Bars in the second rows: 20 μm. Bars in the bottom rows: 50 μm. (C) The TUNEL assay showed no significant difference between pazopanib- and vehicle control-treated xenografts. n.s.; not significant. (D) Ki-67 staining showed significantly suppressed cell cycles in pazopanib-treated xenografts. * P < 0.05. (E) Western blot analyses of Hewga-CCS xenografts. Xenografted mice were treated with 100 mg/kg of pazopanib or vehicle control orally once a day for 1 week, sacrificed 3 h after final administration, and subjected to Western blot analyses.

Back to article page